A

fter U.K. health officials declared an impasse over the cost of a Vertex Pharmaceuticals (VRTX) drug, the chief executive of the company urged U.K. Prime Minister Theresa May to reverse the decision, but also questioned the commitment her government has to biotech investment in the country.

In a Friday letter to May, Jeff Leiden maintained Vertex made “the most innovative and best offer in the world” to the National Health Service for the Orkambi cystic fibrosis medicine, but he complained the health agency has shown “no flexibility by adhering to arbitrary value thresholds.”

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy